Investor Presentaiton
LSI Segment Highlights - Q3'FY20
Particulars¹
Q3'FY19
Q3'FY20 % Change
899
797
(11%)
252
293
16%
106
124
17%
541
381
(30%)
126
100
(21%)
14.0%
12.6%
Revenue
Specialty Intermediates
Nutritional Products
Life Science Chemicals
Reported EBITDA
Reported EBITDA Margin (%)
Revenue Breakup by End-Use Industries
28% 27% 24% 23%
16%
13%
34% 33%
1% 1%
Pharma
Agro
Nutrition Personal Specialty
Care Chemicals
Q3'FY19 Q3'FY20
592
477
Geography Wise Revenue¹
178 163
50
48
79 110
India
North
America
Europe &
Japan
ROW
Q3'FY19 Q3'FY20
1. All figures are in Rs Crore unless otherwise stated
LSI revenue at Rs 797 Crore, decreased by 11% YoY and increased by
6% QoQ. Strong growth witnessed in Specialty Intermediates and
Nutritional Products amid lower revenue in Life Science Chemicals
Specialty Intermediates
.
Revenue increased by 16% YoY led by strong demand and better
prices in key products such as Pyridine, Beta and Pyridine
derivatives
Positive traction for new pyridine derivatives launched in last
year
Ministry of Commerce (MOFCOM) China terminated the 17.6%
anti-dumping duty on imported pyridine during the quarter
Nutritional Products
Revenue increased by 17% YoY led by better prices of Vitamin B3
Demand scenario is expected to be strong in Q4 FY'20
Life Science Chemicals
.
Revenue decreased by 30% YoY due to similar drop in input
prices of Acetic Acid, which led to price correction of Life sciences
chemicals products
Demand for Acetic Anhydride remained subdued during the
quarter
EBITDA at Rs 100 Crore decreased by 21% YoY and increased by 10%
QoQ with margin of 12.6% as compared to 14% in Q3'FY19
.
Strong growth in profitability in Specialty Intermediates and
Nutritional Products businesses
LSC profitability impacted due to significantly higher molasses
prices and lower contribution in acetyl business due to subdued
demand in export market
LIFESCIENCESView entire presentation